Tevimbra® (tislelizumab-jsgr) – New drug approval
March 14, 2024 - BeiGene announced the FDA approval of Tevimbra (tislelizumab-jsgr), as a single agent, for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.
Top